Tracleer

Tracleer is used to treat patients with class III pulmonary arterial hypertension (PAH) to improve exercise capacity (the ability to carry out physical activity) and reduce symptoms. PAH is abnormally high blood pressure in the arteries of the lungs. The ‘class’ reflects the severity of the disease: ‘class III’ PAH involves marked limitation of physical activity. The PAH can be: - primary (with no identified cause or inherited); - caused by scleroderma (also called systemic sclerosis, a disease where there is abnormal growth of the connective tissue that supports the skin and other organs); - caused by congenital (inborn) heart defects with shunts (abnormal passageways) causing abnormal flow of blood through the heart and Some improvement with Tracleer can also occur in patients with class II PAH. ‘Class II’ involves slight limitation of physical activity. Tracleer can also be used in adults with systemic sclerosis in whom poor blood circulation caused by the disease has led to the development of digital ulcers (sores on the fingers and toes). Tracleer is given to reduce the number of new digital ulcers. Tracleer contains the active substance bosentan.